SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
We will happily help you address any related inquires. Please fill in the below form and submit your inquiry.
Address 1
Jacqueline Postma, Ph.D.
Grant manager LUDC
Project manager IMI-SUMMIT
Lund University Diabetes Centre
CRC, Malmö University Hospital
Jan Waldenströms gata 35
SE-205 02 Malmö, Sweden
Tel: +46 (0)40 391236
Fax: +46 (0)40 391222
mailto: jacqueline.postma@med.lu.se
Address 2
Dr. Markus Albertini
Project Manager IMI-SUMMIT
Boehringer Ingelheim Pharma GmbH & Co. KG
Div. Research Germany
Tel.: +49 (7351) 54-97371
Fax: +49 (7351) 83-97371
mailto: summit@boehringer-ingelheim.com
Social Links
google +
Contact Us
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.
Related Sites
